GlassScriptPhysician profile
Daniel R Monette
NPI 1336112531
$16,757.34
in general payments reported to CMS, 2019-2025
70 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,722 · 2020: $1,891 · 2021: $1,786 · 2022: $1,869 · 2023: $2,698 · 2024: $3,029 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,378 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,378.46 |
| Education | $110.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,884.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,317.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,258.35 | 2019-2025 | |
| Lilly USA, LLC | $1,364.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,144.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $873.61 | 2019-2025 | |
| Amgen INC. | $802.55 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $633.23 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $622.53 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $394.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $331.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $302.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $253.13 | 2020-2023 | |
| Amarin Pharma, INC. | $161.04 | 2019-2021 | |
| Exact Sciences Corporation | $141.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Monette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.